News

Through using LentiVector platform, Oxford BioMedica has developed OXB-102 gene therapy for Parkinson’s disease. OXB-102, now renamed AXO-Lenti-PD, is a lentiviral gene therapy with a clinically validated mechanism

This round of financing was led by Yuexiu New Industrial Investment, followed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment. The proceeds will be

Additionally, all ranked secondary endpoints were met. The ongoing study evaluates upadacitinib, an investigational oral JAK1-selective inhibitor, as a monotherapy treatment compared to methotrexate monotherapy in adult patients

The US pharma giant will allocate nearly a quarter of this investment, about $150m on neuroscience. The company will also invest on other therapeutic areas of interest like

Each of the company’s current investors participated in the financing, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures, and Schrödinger. Bruce Booth,

Under the terms of the agreement, Gilead will provide an upfront payment of $10 million. Additionally, Hookipa will be eligible to receive milestone payments based upon the achievement

The Swiss drugmaker had submitted a supplemental biologics license application to the US regulator, covering the data recorded from the phase 3 Haven 3 study. Hemlibra’s priority review

Fulphila, which secured approval to reduce the duration of febrile neutropenia in patients treated with chemotherapy in certain types of cancer, has been co-developed by Mylan and Biocon. It is

This new funding will enable the company to finance the two first Phase II clinical trial of its EYP001 asset in both chronic hepatitis B (HBV) and NASH.